Which SVT drug do patients prefer? small study aims to find out
NCT ID NCT07086560
First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 2 times
Summary
This study looks at two common emergency room drugs for a fast heart condition called SVT: adenosine and diltiazem. Adenosine can cause scary side effects like a feeling of doom, while diltiazem may lower blood pressure. Researchers will review medical records and ask 20 patients about their satisfaction with the treatment they received. The goal is to understand which drug patients prefer and how safe each one is.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- adenosine and diltiazem
- What this could lead to
- If successful, this study could help doctors choose the SVT treatment that patients prefer and tolerate better.
- What could go wrong
- This is a small, observational study (20 people) that looks back at past treatments, so it cannot prove one drug is better. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients (≥18 years of age) treated for SVT in the ED. The investigators will screen a convenience sample of adult patients presenting with stable SVT in the ED for study eligibility while study investigators (most often emergency medicine clinical pharmacists) are available to enroll participants and administer study questionnaires.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. ED encounter for acute SVT 2. Age \>/= 18 years 3. Receipt of IV adenosine and/or IV diltiazem for SVT in the ED or prehospital setting Exclusion Criteria: 1. Neurologic status precluding survey participation due to medical instability 2. Pregnant 3. Incarcerated 4. Non-English speaking
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Supraventricular tachycardia (SVT) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Iowa Health Care
RECRUITINGIowa City, Iowa, 52242, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.